Lexeo Therapeutics reported positive interim data for LX‑2006, a cardiomyopathy gene therapy for Friedreich ataxia, and said U.S. FDA discussions indicated the program may be eligible for an accelerated approval path if datasets are pooled across ongoing studies. The company presented improvements in cardiac and neurologic measures and received guidance that could shorten its route to a Biologics License Application. The FDA’s openness to an accelerated pathway underscores regulatory willingness to consider surrogate or pooled end points for ultra‑rare genetic conditions. Lexeo’s stock reacted strongly to the news. The agency’s signals are consequential for other developers of N‑of‑1 and rare‑disease gene therapies as sponsors seek regulatory strategies that balance expedited access with robust evidence of clinical benefit.